Background: Autoimmune hemolytic anemia (AIHA) is a rare autoimmune disease in which autoantibodies target red blood cells leading to marked decrease in their lifespan. The classification of AIHA is based on the immunochemical properties of the RBC autoantibody. Warm antibody AIHA (wAIHA) accounts for 75-80% of all adult AIHA cases. The treatment of wAIHA is mainly corticosteroids. Our retrospective study aimed to study the clinical profile and management of wAIHA.
Methods: Data of 75 patients admitted with wAIHA or presented to outpatient department (previous medical records) with wAIHA between January 2003 and January 2016 were analyzed.
Results: In our study, females constituted 12 and 26 patients of primary and secondary wAIHA, while males constituted 17 and 20 patients of primary and secondary wAIHA, respectively. Mean hemoglobin level at AIHA onset was found to be 7.1 ± 1.7 g/dL in primary wAIHA group and 6.3 ± 1.2 g/dL in secondary wAIHA group, which is statistically significant. Splenectomy was used as mode of treatment in one (3.4%) patient of primary wAIHA group and 15 (32.60%) patients of secondary wAIHA group, which is statistically significant. Mean age of wAIHA onset was 69.7 ± 21.5 years in wAIHA group secondary to lymphoma and 54.3 ± 25.7 years in other wAIHA group, which is statistically significant.
Conclusion: The most common causes of secondary wAIHA are B-cell lymphoma, systemic lupus erythematosus, rheumatoid arthritis, chronic lymphocytic leukemia (CLL), common variable immune deficiency, renal cell carcinoma and secondary to drug usage (alpha methyldopa and carbamazepine), respectively. Reducing the cumulative dose of corticosteroids with second line treatment whenever possible and therefore reducing the risk of sepsis, specifically in older patients with comorbidities will reduce morbidity and mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155818 | PMC |
| http://dx.doi.org/10.14740/jh303w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia.
Blood
November 2024
Mayo Clinic, Rochester, Minnesota, United States.
Article Synopsis
- This study tested pegcetacoplan, a targeted therapy aimed at treating these conditions, over 48 weeks in two patient groups with CAD and wAIHA who received either 270 or 360 mg/day.
- Results showed that pegcetacoplan was generally well tolerated with minimal serious side effects, and it effectively increased hemoglobin levels and reduced hemolysis in both groups.
Anti-B-Cell-Activating Factor (BAFF) Therapy: A Novel Addition to Autoimmune Disease Management and Potential for Immunomodulatory Therapy in Warm Autoimmune Hemolytic Anemia.
Biomedicines
July 2024
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Although rituximab is not specifically approved for the treatment of warm autoimmune hemolytic anemia (WAIHA), the First International Consensus Group recommends considering its use as part of the initial therapy for patients with severe disease and as a second-line therapy for primary WAIHA. Some patients do not respond to rituximab, and relapses are common. These relapses are associated with elevated B-cell-activating factor (BAFF) levels and the presence of quiescent long-lived plasma cells (LLPCs) in the spleen.
View Article and Find Full Text PDFAutoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.
Int J Mol Sci
April 2024
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5B 1W8, Canada.
Article Synopsis
- Autoimmune hemolytic anemias (AIHAs) involve the immune system producing antibodies that attack the body's own red blood cells, categorized mainly into warm and cold antibody types, as well as mixed forms.
- Treatment varies depending on the type, often including glucocorticoids and monoclonal antibodies, with the direct antiglobulin test (DAT) playing a key role in diagnosis.
- Additional complexities include drug-induced AIHA and conditions like passenger lymphocyte syndrome, highlighting the need for tailored management strategies based on the specific AIHA category.
Role of direct antiglobulin test in anemia under evaluation: Its prevalence, laboratory workup, and significance in further patient management-A study from eastern India.
Indian J Pathol Microbiol
July 2024
Community Medicine, Medical College Kolkata, West Bengal, India.
Introduction And Aims: The direct antiglobulin test (DAT) is an important diagnostic tool for immune hemolytic anemia (IHA). The present study was primarily aimed to identify the prevalence of DAT positivity in anemia patients along with its specificity . A three months follow up of the DAT positive patients were performed for the response during course of illness in terms of transfusion requirement, hemoglobin level, persistence of DAT.
View Article and Find Full Text PDFHealthcare resource utilization of patients with warm autoimmune hemolytic anemia initiating first line therapy of oral corticosteroids with or without rituximab.
Ann Hematol
April 2024
Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA.
This retrospective cohort study described real-world treatment patterns and healthcare resource utilization (HCRU) of patients with warm autoimmune hemolytic anemia (wAIHA) initiating treatment with first-line (1L) oral corticosteroids (OCS) + rituximab (R) compared to 1L OCS. Patients with a wAIHA diagnosis code (D59.11) between 8/2020-3/2022 were identified using US pharmacy and medical claims databases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!